Gilead Sciences (GILD): Highlights From Management Vsit - RBC

RBC Capital analyst, Brian Abrahams, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) after meeting with senior management and leaving with "increased confidence in the near-term positive
drivers—Biktarvy's launch and NASH/inflammation clinical data—as well as the long-term competitive positioning that could drive revenue sustainability".

The analyst stated "With no drug-drug interactions, no renal compromise, and lack of liver tox/monitoring, Biktarvy is being positioned by GILD as the optimal therapy for all treatment-naive HIV pts, which we believe will enable
it to take substantial share over time".

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $79.32 yesterday.

You May Also Be Interested In

• BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy
• iRhythm Technologies (IRTC) PT Lowered to $190 at Freedom Capital
• Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight